BSBE Guest Seminar丨Dr. Dengfeng DOU from HitGen Inc. Release Time：2023-12-20

ABSTRACT

DNA encoded library (DEL), merging combinatorial chemistry and molecular biology, has been a mature technology for ligand discovery after serval years’ intensive industrial practice. It utilizes very small amount of target/protein to access up to trillions of physical molecules, providing a very powerful and efficient tool for functional hit identification for almost any type of targets in various formats. DEL is able to do multiple screening in parallel, therefore providing extraordinary ligand selectivity knowledge during the selection without extra cost. HitGen is one of the leaders in DEL technology field, providing the largest DEL in the world and OpenDEL™ for academic use to facilitate your research work. The presentation by Dr. Dengfeng Dou will focus on the principle and application of DEL technology.

BIOGRAPHY

Dr. Dengfeng Dou received his PhD degree in Bioorganic and Medicinal Chemistry at Wichita State University, KS, USA, and his research areas included COPD related inflammation and antiviral agents drug discovery. He finished his postdoctoral training in selective anti-malarial agent discovery at Mayo Clinic, MN, USA. Prior to his PhD and Postdoc, he has 7 years’ peptide library synthesis and API GMP manufacture experiences at Chengdu Di’Ao Pharmaceutical Company, Sichuan, China.

Dr. Dou joined HitGen in August 2012 and has been deeply involved in many HitGen Medicinal Chemistry projects. He has led HitGen Project Management Department focusing on company portfolio management and external collaboration till September 2016. Then he was appointed as the head of Lead Generation Unit (LGU) focusing on novel hit/lead discovery and lead optimization using DNA encoded library (DEL) technology. LGU provided high quality services to many international and domestic pharma, biotech companies and research institutes. Recently, he has led LGU to extend its business to Targeted Protein Degradation (TPD), focusing on novel E3 ligase ligand discovery and validation, DEL-driven novel degrader discovery and development.